Agenus (AGEN) Return on Capital Employed (2011 - 2026)
Agenus (AGEN) posted quarterly Return on Capital Employed of 19.23% for Q1 2026, up 202667.0% year-over-year from N/an in Q1 2025, and down 188.83% quarter-over-quarter from 21.65% in Q4 2025.
Agenus (AGEN) Return on Capital Employed (2011 - 2026) Analysis & Trends
Agenus' Return on Capital Employed history runs 16 years deep, the most recent figure standing at 19.23% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 202667.0% year-over-year to 19.23%; the TTM figure through Mar 2026 stood at 19.23% (up 202667.0% YoY), while the FY2025 annual figure was 20.8%, up 26823.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 19.23%, down from 21.65% in the prior quarter.
- The five-year high for Return on Capital Employed was 21.65% in Q4 2025, with the low at 2973.49% in Q2 2024.
- The 5-year median for Return on Capital Employed is 52.78% (2023), against an average of 428.5%.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed sank 292071 bps in 2024, then jumped 292738 bps in 2025.
- Agenus' Return on Capital Employed stood at 42.95% in 2022, then slumped by 440 bps to 231.92% in 2023, then sank by 373 bps to 1097.67% in 2024, then jumped by 102 bps to 21.65% in 2025, then sank by 189 bps to 19.23% in 2026.
- Business Quant data shows AGEN's Return on Capital Employed at 19.23% in Q1 2026, 21.65% in Q4 2025, and 28.94% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Agenus | 311.95 Mn | 286.43 Mn | 34.52 Mn | -69.29% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -69.29% |
| Mar 31, 2026 | -19.23% |
| Dec 31, 2025 | 21.65% |
| Sep 30, 2025 | -28.94% |
| Jun 30, 2025 | -46.11% |
| Mar 31, 2025 | -2,045.90% |
| Dec 31, 2024 | -1,097.67% |
| Sep 30, 2024 | -37.64% |
| Jun 30, 2024 | -2,973.49% |
| Mar 31, 2024 | -472.36% |
| Dec 31, 2023 | -231.92% |
| Sep 30, 2023 | -132.22% |
| Jun 30, 2023 | -52.78% |
| Mar 31, 2023 | -89.20% |
| Dec 31, 2022 | -42.95% |
| Sep 30, 2022 | -65.19% |
| Jun 30, 2022 | 18.51% |
| Mar 31, 2022 | 10.89% |
| Dec 31, 2021 | 8.73% |
| Sep 30, 2021 | 35.23% |